Analysts See $-0.05 EPS for Protalix BioTherapeutics, Inc. (PLX)

July 13, 2018 - By Jenna Rose

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Logo

Analysts expect Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) to report $-0.05 EPS on August, 8.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $-0.06 EPS. After having $-0.06 EPS previously, Protalix BioTherapeutics, Inc.’s analysts see -16.67 % EPS growth. The stock decreased 2.47% or $0.01 during the last trading session, reaching $0.45. About 178,474 shares traded. Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) has declined 50.88% since July 13, 2017 and is downtrending. It has underperformed by 63.45% the S&P500.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company has market cap of $65.48 million. The firm offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. It currently has negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.